Uterine Fibroids Market

The global Uterine Fibroids market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The USA market for Global Uterine Fibroids market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The China market for Global Uterine Fibroids market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The Europe market for Global Uterine Fibroids market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

Uterine fibroids (myoma) are benign (non-cancerous) lumps that grow in the muscular wall of the uterus. They vary in sizes, from minute (a quarter of an inch) to the size of more than16 centimeters. The incidence of uterine fibroid is about 20%?40% in women during their reproductive ages. Occasionally, these fibroids swell up and make the uterus to grow like full visible pregnancy. Mostly, there are more than one fibroid in the uterus. However, fibroids do not always cause any symptoms, their location, and size results to difficulties for few women, including pain, discomfort and heavy bleeding. Uterine fibroid can be of different types such as intramural fibroids, subserosal fibroids, pedunculated fibroids and submucosal fibroids. There can be many reasons for uterine fibroid formation but genetic problems hormonal imbalance and other factors are predominant. The cardinal symptoms of uterine fibroids are heavy menstrual bleeding, abdominal pain, excessive uterine bleeding, increased urinary frequency, anaemia and infertility. Apart from physical morbidity, uterine fibroid ailment is a frequent cause of significant damage of quality of life and a major reason for hysterectomy. Therapy has traditionally based on two extremes: medicinal management, comprising progestins, oral contraceptives and GnRH agonists and surgical management, including myomectomy, hysterectomy, and ablation for most serious cases.
Uterine Fibroids Market aims to provide a comprehensive presentation of the global market for Uterine Fibroids, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Uterine Fibroids. Uterine Fibroids Market contains market size and forecasts of Uterine Fibroids in global, including the following market information:

• Global Uterine Fibroids Market Revenue, 2018-2023, 2024-2030, ($ millions)
• Global top five companies in 2022 (%)

• Non-Hormonal Treatment
• Hormonal Treatment

• Hospitals
• Ambulatory Surgical Centers
• Diagnostic Centers
• Others

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
• The Middle East and Africa (Middle East, Africa)
• South and Central America (Brazil, Argentina, Rest of SCA)

• Key companies Uterine Fibroids revenues in global market, 2018-2023 (estimated), ($ millions)
• Key companies Uterine Fibroids revenues share in global market, 2022 (%)

• Boston Scientific
• Cooper Surgical
• C.R. Bard
• F. Hoffmann-La Roche
• GE Healthcare
• Karl Storz Endoscopy
• Richard Wolf Medical Instruments
• Siemens Medical Solutions
• AbbVie
• AstraZeneca
• Bayer
• Eli Lilly
• GlaxoSmithKline Pharmaceuticals
• Pfizer
• Johnson & Johnson
• Novartis